5-132595759-TAA-TAAA
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PVS1PP5
The NM_005732.4(RAD50):c.2165dupA(p.Glu723fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000198 in 1,598,140 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.00014 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00020 ( 0 hom. )
Consequence
RAD50
NM_005732.4 frameshift
NM_005732.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -0.126
Genes affected
RAD50 (HGNC:9816): (RAD50 double strand break repair protein) The protein encoded by this gene is highly similar to Saccharomyces cerevisiae Rad50, a protein involved in DNA double-strand break repair. This protein forms a complex with MRE11 and NBS1. The protein complex binds to DNA and displays numerous enzymatic activities that are required for nonhomologous joining of DNA ends. This protein, cooperating with its partners, is important for DNA double-strand break repair, cell cycle checkpoint activation, telomere maintenance, and meiotic recombination. Knockout studies of the mouse homolog suggest this gene is essential for cell growth and viability. Mutations in this gene are the cause of Nijmegen breakage syndrome-like disorder.[provided by RefSeq, Apr 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 5-132595759-T-TA is Pathogenic according to our data. Variant chr5-132595759-T-TA is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 141045.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=1, Pathogenic=11}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD50 | NM_005732.4 | c.2165dupA | p.Glu723fs | frameshift_variant | 13/25 | ENST00000378823.8 | NP_005723.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD50 | ENST00000378823.8 | c.2165dupA | p.Glu723fs | frameshift_variant | 13/25 | 1 | NM_005732.4 | ENSP00000368100.4 | ||
ENSG00000283782 | ENST00000640655.2 | c.1868dupA | p.Glu624fs | frameshift_variant | 14/26 | 5 | ENSP00000491596.2 |
Frequencies
GnomAD3 genomes AF: 0.000140 AC: 21AN: 150326Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
21
AN:
150326
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000271 AC: 65AN: 239710Hom.: 0 AF XY: 0.000246 AC XY: 32AN XY: 129936
GnomAD3 exomes
AF:
AC:
65
AN:
239710
Hom.:
AF XY:
AC XY:
32
AN XY:
129936
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000204 AC: 295AN: 1447814Hom.: 0 Cov.: 31 AF XY: 0.000180 AC XY: 130AN XY: 720476
GnomAD4 exome
AF:
AC:
295
AN:
1447814
Hom.:
Cov.:
31
AF XY:
AC XY:
130
AN XY:
720476
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000140 AC: 21AN: 150326Hom.: 0 Cov.: 32 AF XY: 0.000136 AC XY: 10AN XY: 73306
GnomAD4 genome
AF:
AC:
21
AN:
150326
Hom.:
Cov.:
32
AF XY:
AC XY:
10
AN XY:
73306
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:12Uncertain:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Nijmegen breakage syndrome-like disorder Pathogenic:7
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Apr 20, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Oct 03, 2022 | PVS1, PS3, PM2 - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 22, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 26, 2024 | - - |
Pathogenic, criteria provided, single submitter | curation | Sema4, Sema4 | Oct 13, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Apr 21, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Apr 04, 2024 | - - |
not provided Pathogenic:2Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Nov 19, 2021 | The frequency of this variant in the general population, 0.00042 (8/19162 chromosomes, http://gnomad.broadinstitute.org), is consistent with pathogenicity. In the published literature, the variant has been reported in individuals with breast or ovarian cancer (PMIDs: 31742824 (2020), 26824983 (2016), and 25452441 (2015)). Based on the available information, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneKor MSA | Jan 01, 2020 | This variant is a duplication of 1 nucleotide in exon 13 of RAD50 mRNA (c.2165dupA). causing a frameshift at codon 723. This creates a premature translational stop signal (p.Glu723Glyfs*5) and is expected to result in an absent or disrupted protein product. Truncating mutations in RAD50 are known to be pathogenic. The mutation database ClinVar contains an entry for this variant (Variation ID: 37377/). - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 03, 2023 | Variants in candidate genes are classified as variants of uncertain significance in accordance with ACMG guidelines (Richards et al., 2015); Frameshift variant predicted to result in protein truncation and nonsense mediated decay in a gene or region of a gene for which loss of function is not a well-established mechanism of disease; Observed in individuals with breast and/or ovarian cancer (Couch et al., 2015; Lin et al., 2016; Lilyquist et al., 2017; Goidescu et al., 2018); This variant is associated with the following publications: (PMID: 32832836, 26824983, 30755392, 31159747, 26689913, 33378670, 35768433, 34803902, 34680501, 29739316, 35595529, 29566657, 31742824, 33804961, 29726012, 32295079, 25452441, 16385572, 29785153, 28888541) - |
Hereditary cancer-predisposing syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 11, 2023 | This sequence change creates a premature translational stop signal (p.Glu723Glyfs*5) in the RAD50 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAD50 are known to be pathogenic (PMID: 19409520). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 25452441, 26824983). This variant is also known as c.2157dupA. ClinVar contains an entry for this variant (Variation ID: 141045). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 13, 2022 | The c.2165dupA pathogenic mutation, located in coding exon 13 of the RAD50 gene, results from a duplication of A at nucleotide position 2165, causing a translational frameshift with a predicted alternate stop codon (p.E723Gfs*5). This alteration has been reported multiple individuals diagnosed with breast or prostate cancer (Lin PH et al. Oncotarget. 2016 Feb;7:8310-20; Fan C et al. Int J Cancer, 2018 10;143:1935-1942; Goidescu IG et al. Clujul Med, 2018 Apr;91:157-165; Wang YA et al. BMC Cancer, 2018 03;18:315; Matejcic M et al. JCO Precis Oncol, 2020 Jan;4:32-43). This alteration was also identified in trans with c.3109_3111del in an individual with bone marrow failure, microcephaly, skin pigmentation, nail dysplasia, dental loss and dysmorphia (Chansel-Da Cruz M et al. Cell Rep, 2020 12;33:108559). Of note, this alteration is also known as c.2157dupA in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Breast and/or ovarian cancer Pathogenic:1
Pathogenic, no assertion criteria provided | case-control | CZECANCA consortium | Jun 11, 2019 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at